Yong Ma

Dr. Yong Ma

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2018 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
DSDian Su
Dian Su
KKKatherine R. Kozak
Katherine R. Kozak
JSJack Sadowsky
Jack Sadowsky
SYShang-Fan Yu
Shang-Fan Yu
AFAimee Fourie-O’donohue
Aimee Fourie-O’donohue
TPThomas H. Pillow
Thomas H. Pillow

1 July 2014 in Life Sciences
Verified
Journal Article
Closed access
SGSong Gao
Song Gao
TYTaijun Yin
Taijun Yin
BXBeibei Xu
Beibei Xu
YMYong Ma
Yong Ma
MHMing Hu
Ming Hu

26 August 2016 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DZDonglu Zhang
Donglu Zhang
TPThomas H. Pillow
Thomas H. Pillow
YMYong Ma
Yong Ma
JCJosefa Dela Cruz-Chuh
Josefa Dela Cruz-Chuh
KKKatherine R. Kozak
Katherine R. Kozak
PDPeter S. Dragovich
Peter S. Dragovich

7 February 2018 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
DZDonglu Zhang
Donglu Zhang
HLHoa Le
Hoa Le
JCJosefa Dela Cruz-Chuh
Josefa Dela Cruz-Chuh
SBSudheer Bobba
Sudheer Bobba
JGJun Guo
Jun Guo
TPThomas Pillow
Thomas Pillow

27 June 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YMYong Ma
Yong Ma
YFYue Fu
Yue Fu
SKS. Cyrus Khojasteh
S. Cyrus Khojasteh
DDDeepak Dalvie
Deepak Dalvie
DZDonglu Zhang
Donglu Zhang

1 September 2016 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
DZDonglu Zhang
Donglu Zhang
SYShang-Fan Yu
Shang-Fan Yu
YMYong Ma
Yong Ma
KXKeyang Xu
Keyang Xu
PDPeter S. Dragovich
Peter S. Dragovich
CKCyrus Khojasteh
Cyrus Khojasteh
Despite recent technological advances in quantifying antibody drug conjugate (ADC) species, such as total antibody, conjugated antibody, conjugated drug, and payload drug in circulation, the correlation of their exposures with the efficacy of ADC outcomes in vivo remains challenging. Here, the chemical structures and concentrations of intratumor catabolites were investigated to better understand the drivers of ADC in vivo efficacy. Anti-CD22 disulfide-linked pyrrolobenzodiazepine (PBD-dimer) conjugates containing methyl- and cyclobutyl-substituted disulfide linkers exhibited strong efficacy in a WSU-DLCL2 xenograft mouse model, whereas an ADC derived from a cyclopropyl linker was inactive. Total ADC antibody concentrations and drug-to-antibody ratios (DAR) in circulation were similar between the cyclobutyl-containing ADC and the cyclopropyl-containing ADC; however, the former afforded the release of the PBD-dimer payload in the tumor, but the latter only generated a nonimmolating thiol-containing catabolite that did not bind to DNA. These results suggest that intratumor catabolite analysis rather than systemic pharmacokinetic analysis may be used to better explain and predict ADC in vivo efficacy. These are good examples to demonstrate that the chemical nature and concentration of intratumor catabolites depend on the linker type used for drug conjugation, and the potency of the released drug moiety ultimately determines the ADC in vivo efficacy.